# A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France

> **NCT06949358** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 3 (actual)

## Conditions studied

- Acid Sphingomyelinase Deficiency

## Interventions

- **DRUG:** Olipudase alfa

## Key facts

- **NCT ID:** NCT06949358
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-18
- **Primary completion:** 2025-04-08
- **Final completion:** 2025-04-08
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06949358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06949358, "A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06949358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*